Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

烟民心梗应用氯吡格雷和他汀获益大！高润霖院士等发表CPACS-3研究

2020-05-08 朱朱 中国循环杂志

氯吡格雷他汀
关注

既往发现，经细胞色素P450酶代谢的一些药物尤其氯吡格雷，在吸烟患者中的疗效高于不吸烟的患者，但这在亚洲患者中证据有限。

既往发现，经细胞色素P450酶代谢的一些药物尤其氯吡格雷，在吸烟患者中的疗效高于不吸烟的患者，但这在亚洲患者中证据有限。
 
近日，阜外医院高润霖院士、北京大学临床研究所武阳丰教授等开展的CPACS-3研究显示，在我国急性心肌梗死患者中，在降低院内死亡风险上，氯吡格雷和他汀类药物在吸烟患者中的效果优于不吸烟患者。
 
但同样作为经细胞色素P450酶代谢的药物，钙拮抗剂对吸烟和不吸烟急性心肌梗死患者院内死亡风险的降低作用没有明显差别。
 
CPACS-3研究为一项全国性的大规模前瞻性队列研究，从全国101家医院一共纳入14 658例急性心肌梗死患者。
 
住院期间，接受氯吡格雷、他汀类药物、钙拮抗剂治疗的患者分别占86%、93%和10%。
 
在吸烟患者中，与未接受氯吡格雷治疗的患者相比，接受该药治疗的患者院内死亡风险降低了39%。但在不吸烟患者中，接受和未接受氯吡格雷治疗者的院内死亡风险相似。
 
同样，在吸烟患者中，与未接受他汀治疗的患者相比，接受该药治疗的患者院内死亡风险降低了55%。但在不吸烟患者中，两类患者的院内死亡风险无明显差别。
 
来源：Influences of Smoking Status on Effectiveness of Cytochrome P450 Enzyme System Metabolized Medications in Reducing In-Hospital Death in 14 658 Patients With Acute Myocardial Infarction: Data From CPACS-3 Study. J Cardiovasc Pharmacol Ther, First Published April 26, 2020

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811451, encodeId=b485181145193, content=<a href='/topic/show?id=ca0c88041e0' target=_blank style='color:#2F92EE;'>#获益大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88041, encryptionId=ca0c88041e0, topicName=获益大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 11 05:58:19 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659528, encodeId=9e4816595288b, content=<a href='/topic/show?id=806510246e98' target=_blank style='color:#2F92EE;'>#高润霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102467, encryptionId=806510246e98, topicName=高润霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061a24999434, createdName=fengyi820, createdTime=Wed Nov 25 18:58:19 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279346, encodeId=455112e934643, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun May 10 05:58:19 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049216, encodeId=15cf1049216d9, content=院士是学术至高点，也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri May 08 17:58:19 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-09-11 医者仁心

    #获益大#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1811451, encodeId=b485181145193, content=<a href='/topic/show?id=ca0c88041e0' target=_blank style='color:#2F92EE;'>#获益大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88041, encryptionId=ca0c88041e0, topicName=获益大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 11 05:58:19 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659528, encodeId=9e4816595288b, content=<a href='/topic/show?id=806510246e98' target=_blank style='color:#2F92EE;'>#高润霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102467, encryptionId=806510246e98, topicName=高润霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061a24999434, createdName=fengyi820, createdTime=Wed Nov 25 18:58:19 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279346, encodeId=455112e934643, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun May 10 05:58:19 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049216, encodeId=15cf1049216d9, content=院士是学术至高点，也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri May 08 17:58:19 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-11-25 fengyi820

    #高润霖#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1811451, encodeId=b485181145193, content=<a href='/topic/show?id=ca0c88041e0' target=_blank style='color:#2F92EE;'>#获益大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88041, encryptionId=ca0c88041e0, topicName=获益大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 11 05:58:19 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659528, encodeId=9e4816595288b, content=<a href='/topic/show?id=806510246e98' target=_blank style='color:#2F92EE;'>#高润霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102467, encryptionId=806510246e98, topicName=高润霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061a24999434, createdName=fengyi820, createdTime=Wed Nov 25 18:58:19 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279346, encodeId=455112e934643, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun May 10 05:58:19 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049216, encodeId=15cf1049216d9, content=院士是学术至高点，也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri May 08 17:58:19 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-10 yaanren

    #ACS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1811451, encodeId=b485181145193, content=<a href='/topic/show?id=ca0c88041e0' target=_blank style='color:#2F92EE;'>#获益大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88041, encryptionId=ca0c88041e0, topicName=获益大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 11 05:58:19 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659528, encodeId=9e4816595288b, content=<a href='/topic/show?id=806510246e98' target=_blank style='color:#2F92EE;'>#高润霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102467, encryptionId=806510246e98, topicName=高润霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061a24999434, createdName=fengyi820, createdTime=Wed Nov 25 18:58:19 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279346, encodeId=455112e934643, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun May 10 05:58:19 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049216, encodeId=15cf1049216d9, content=院士是学术至高点，也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri May 08 17:58:19 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 junJUN

    院士是学术至高点，也是大家必争之地呀

    0

相关资讯

J Cardiovasc Pharmacol Ther：烟民心梗应用氯吡格雷和他汀获益大！高润霖院士等发表CPACS-3研究

既往发现，经细胞色素P450酶代谢的一些药物尤其氯吡格雷，在吸烟患者中的疗效高于不吸烟的患者，但这在亚洲患者中证据有限。

服用氯吡格雷可能增加胃溃疡风险，应该如何应对？

氯吡格雷是一种前体药，本身无抗血小板聚集效果，需要经过一种酶作用，氧化后形成中间产物，之后再水解，形成有药理活性的代谢物后，才能迅速、不可逆地与血小板受体结合，抑制血小板聚集。

JACC：吗啡会增加服用氯吡格雷的非ST段抬高型冠心病患者的缺血风险

既往的基础研究已经证明吗啡可以减弱口服二磷酸腺苷受体阻滞剂的抗血小板作用，但是临床的结果却是相反。本研究的目的旨在评估吗啡与接受氯吡格雷治疗的非ST段抬高急性冠脉综合征（NSTEACS）缺血事件发生的相关性。本研究纳入分析了EARLY ACS临床试验中的5438名NSTEACS患者，终点事件是96h的死亡、心梗、反复缺血或血栓性抢救的复合事件，和30天死亡或心梗的复合事件。在接受氯吡格雷治疗的患者

Lancet:70岁以上非ST升高急性冠状动脉综合征患者抗血小板药物选择

对于70岁以上的非ST升高急性冠状动脉综合征，氯吡格雷的治疗受益要优于替卡格雷

JACC: 吗啡和氯吡格雷不要同时用！增加ACS患者缺血事件风险

临床上，吗啡是缓解急性冠脉综合征胸痛的药物之一。但机制性研究显示，吗啡可能会影响口服抗血小板药物（二磷酸腺苷受体拮抗剂）的抗血小板效果。

Heart：氯吡格雷可以降低房颤PCI术后患者出血风险

本研究旨在比较第三代P2Y12抑制剂与氯吡格雷联合口服抗凝（OAC）和阿司匹林治疗经皮冠状动脉介入治疗（PCI）心房颤动（AF）的安全性和有效性。

Baidu
map
Baidu
map
Baidu
map